Pharma channel feed

Roche scores a no­table PhI­II suc­cess with Tecen­triq com­bo in blad­der can­cer, but is this an­oth­er case of too lit­tle too late?

6 years ago
R&D

Dai­ichi Sankyo scores land­mark FDA OK for rare tu­mor drug — al­beit with re­stric­tions

6 years ago

FDA chief backs 2 new path­ways to spur drug im­por­ta­tion — but an­a­lysts shrug it all off

6 years ago
People

Mer­ck­'s Keytru­da makes the cut as a sec­ond-line monother­a­py for cer­tain esophageal can­cer pa­tients

6 years ago

Bay­er, Ori­on win speedy ap­proval for prostate can­cer drug daro­lu­tamide

6 years ago

FTC in­ves­ti­gates J&J con­tracts re­gard­ing the drug­mak­er's block­buster Rem­i­cade

6 years ago
FDA+

What is Pfiz­er go­ing to buy next? Al­bert Bourla out­lines his M&A strat­e­gy in the post-Up­john era

6 years ago
Deals

Thrashed by a 'sur­prise' ri­val, Sanofi writes off $2B on soured he­mo­phil­ia deal

6 years ago

In a first, Lil­ly's ready-to-use res­cue hy­po­glycemia pow­der wins US ap­proval

6 years ago

Bris­tol-My­ers does it again, dis­ap­point­ing in­vestors with a sur­prise Op­di­vo PhI­II fail­ure as chemo com­bo flops

6 years ago
R&D

FDA OKs Hu­mi­ra copy­cat from Mer­ck, Sam­sung Bioepis — but they will wait 4 years to launch

6 years ago

Roche cuts loose Tam­i­flu OTC rights, hand­ing Sanofi the keys as the phar­ma gi­ant dou­bles down on Xofluza

6 years ago
Deals

Aca­dia is mak­ing the best of it, but their lat­est PhI­II Nu­plazid study is a bust

6 years ago
R&D

Take­da re­ports sec­ond PhI­II win for sub­cu­ta­neous En­tyvio as reg­u­la­tors re­view ex­pand­ed use

6 years ago
R&D

Cel­gene racks up third Ote­zla ap­proval, heat­ing up talks about who Bris­tol-My­ers will sell to

6 years ago
Deals

Chas­ing Roche's ag­ing block­buster fran­chise, Am­gen/Al­ler­gan roll out Avastin, Her­ceptin knock­offs at dis­count

6 years ago

Take­da preps an­oth­er drug auc­tion as ex­ecs look to fur­ther trim its post-Shire buy­out debt load — re­port

6 years ago
Deals

Gilead un­leash­es a $5B late-stage cash al­liance with Gala­pa­gos — lay­ing out O'­Day's R&D strat­e­gy

6 years ago
Deals
R&D

ICER up­date on Duchenne drugs push­es up price es­ti­mates for Ex­ondys 51, Em­flaza ahead of Ju­ly pan­el re­view

6 years ago

Analy­sis: In most of the Big Phar­ma world, R&D spend­ing tow­ers over rev­enue from new drugs. Guess who beat the odds

6 years ago
R&D
Biotech Voices

New peanut al­ler­gy ther­a­pies aren’t as ef­fec­tive — or near­ly as in­ex­pen­sive — as ab­sti­nence, says ICER

6 years ago

White House changes course to kill re­bate re­form

6 years ago

Sup­ply con­straints push EpiPen ri­val mak­er Am­neal to re­struc­ture, shares fall

6 years ago

Fed­er­al judge scut­tles Trump's rule man­dat­ing drug prices in TV ads

6 years ago
FDA+
First page Previous page 269270271272273274275 Next page Last page
A service from the Financial Times